Work

Abstract PS5-07-11: A phase 1 study of LY4257496, a novel GRPR-targeted radioligand therapy, in patients with GRPR-positive metastatic ER+ breast cancer and other advanced solid tumors - OMNIRAY (Trial in Progress)

Year: 2026

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-ps5-07-11

Authors: K. Jhaveri, L. Bodei, P. Bedard, K. Jerzak, D. Juric, J. O'Shaughnessy, E. Mayer, N. Harbeck, H. Rugo, A. Bardia, P. Veit-Haibach, P. Heidari, V. Prasad, K. Herrmann, C. Trieu, F. Almaguel

Institutions: Memorial Sloan Kettering Cancer Center, University of Toronto, Princess Margaret Cancer Centre, Sunnybrook Health Science Centre, Dana-Farber Cancer Institute, LMU Klinikum, Ludwig-Maximilians-Universität München, City Of Hope National Medical Center, City of Hope, University of California, Los Angeles, University Health Network, Massachusetts General Hospital, Washington University in St. Louis, Essen University Hospital, Eli Lilly (United States)

Language: English

Topic: Radiopharmaceutical Chemistry and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7129449678

Cites:

Cited by:

Related to: